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Abstract
Background—Varicella vaccine has been available in the private sector in China for a decade as 
a single-dose regimen, but varicella vaccine effectiveness (VE) has not been fully examined in 
school settings yet.
Methods—A matched case–control study was carried out in elementary schools and daycares in 
Tai’an prefecture, Shandong province, China. Clinical diagnosis of varicella and breakthrough 
disease was used for this study. Four controls were randomly selected from classmates; two from 
classmates of the case and two from another class of the same grade without cases. Vaccination 
status, date of vaccination, and vaccine product received if vaccinated were collected from home 
and clinic immunization records. Vaccination status of all students in schools/daycares with 
varicella cases from home immunization records or parental recall was used to calculate 
vaccination coverage.
Results—The overall varicella VE was 83.4% (95% confidence interval 71.4–90.3%). Receipt of 
varicella vaccine five years or more years before the outbreak was significantly associated with 
breakthrough varicella (odds ratio = 4.7, P < 0.001), while age at vaccination (<15 vs. ≥15 
months) was not (odds ratio = 1.5, P = 0.62). Varicella vaccination coverage was 41% with 
substantial variation across schools (range of 0–93.8%).
Conclusions—Single-dose varicella vaccine is highly effective in school settings. Maintaining 
limited vaccination coverage might shift varicella disease burden to older individuals, who are 
more prone to develop severe outcomes if varicella occurs.
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Varicella (chickenpox) is a highly contagious disease caused by infection with varicella 
zoster virus (VZV), and is characterized by a generalized pruritic vesicular rash. Although 
varicella is usually self-limiting and resolves within a week, severe complications, including 
death, can occur [1].
Varicella vaccines are now widely available as the most effective measure for prevention 
and control of varicella. In China, varicella vaccine first became available in 1998. Five 
vaccines are currently licensed in China for single dose use in persons 12 months and older: 
Varilrix® (GlaxoSmithKline) and four domestic vaccines (Baike, Changsheng, Keygen, and 
Shanghai). The five varicella vaccines have similar concentrations of Oka strain VZV: 
>1995 plaque forming unit/dose (0.5 mL) in Varilrix, and >2000 plaque forming unit/dose 
(0.5 ml) in the domestic vaccines. The five vaccines have the same temperature requirement 
(2–8 °C) for cold-chain storage and transportation. Currently, varicella vaccines are only 
available for private purchase in China and vaccination coverage varies substantially by 
regional level of economic development [2–5]. Although their immunogenicity and safety 
have been assessed previously in randomized clinical trials [6–13], the effectiveness of these 
vaccines in China have not yet been fully examined in school settings, the most likely places 
for intense varicella exposure as a consequence of decreasing family sizes in China [14]. A 
matched case–control study was carried out in schools and daycares to examine the post-
licensure effectiveness of varicella vaccines in school settings in Shandong Province, China.
2. Methods
2.1. Study population
The China Center for Disease Control and Prevention (CDC) and Tai’an CDC conducted a 
case–control study in schools and daycare centers in five counties of Tai’an prefecture, 
Shandong province, from 3/2010 to 6/2011. A case of varicella was defined as an acute 
generalized maculopapulovesicular rash without other apparent cause [15]. Breakthrough 
varicella was defined as a case that developed >42 days after vaccination [15]. Although 
varicella was not a notifiable disease in Tai’an prefecture during this period, 248 elementary 
schools and daycare centers in five counties of Tai’an prefecture agreed to report varicella 
cases to the local department of health, whose staff enrolled eligible case-patients and 
controls and interviewed parents/guardians. Informed consent for study participation was 
obtained from parents/guardians. For each enrolled case-patient from an elementary school, 
two classmates sitting directly around the case were randomly selected, and another two 
students from a class of same grade without any varicella cases were also randomly selected 
as controls. Each control group was analyzed separately with the cases to calculate vaccine 
effectiveness and finding no difference, the controls were grouped together. For each case 
from a daycare center, two controls were selected from the case-patient’s classroom and 
another two controls were randomly selected from daycare attendees of the same age from a 
classroom without cases.
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Parents/guardians of the participants were interviewed using a standard questionnaire to 
collect information on sociodemographics, underlying diseases, prior varicella history, and 
recent possible VZV exposure. Case and control candidates with prior varicella history were 
excluded. For enrolled cases and controls, vaccination status, date of vaccination, and 
vaccine product received if vaccinated were collected from immunization records at home or 
in the immunization clinics. Date of rash onset and prior varicella history were collected 
from parents or clinic records. For evaluation of vaccine coverage in the schools and daycare 
centers under study, the vaccination status and prior varicella history were collected from 
immunization records at home or parental recall and vaccination coverage was calculated 
after the outbreak was over and excluded those with prior disease history.
2.3. Statistical analyses
We defined varicella VE as [1 − odds ratio (OR)] × 100%, where OR was calculated from 
conditional logistic regression for the matched case–control study. Vaccine product-specific 
VEs could only be calculated for the Baike and Changsheng vaccines due to the small 
number of participants who had received the other vaccine products. We used previously 
described methods to assess VE changes with time since vaccination [16]. For pairs in which 
either or both the case and the controls had received varicella vaccine, we defined the time 
since vaccination as the time interval between the date(s) of vaccination and the rash onset 
date of the matched case. For assessing vaccination status of controls, we used the date of 
rash onset in the case as the reference date. Thus, controls who received varicella vaccine 
after the disease onset date of the matched case were defined as unvaccinated. We 
performed all analyses with SAS version 9.2 (SAS Inc., Cary, NC).
China CDC Ethics Committee reviewed and approved this protocol.
3. Results
3.1. Characteristics of the study participants
There were a total of 180 cases reported from 44 schools and day cares and 679 controls 
enrolled. Half (434, 50.5%) of the 859 participants were female. The majority of participants 
were elementary school students (589, 68.6%) with a mean age of 7.3 years (range: 1.3–
12.4). Five participants reported having underlying medical conditions of asthma and 
eczema. More than half of the cases (97/180) reported a VZV exposure, 93 (95.9%) of 
which were at school. Of the 250 (29.1%) vaccinated cases and controls, 135 (54.0%) 
received Changsheng vaccine and 83 (33.2%) received Baike vaccine (Table 1). There were 
no differences between cases and controls by sex, age, age at vaccination, or type of vaccine 
product received. However, cases were less likely to be vaccinated than controls (10.0% vs. 
34.5%, P < 0.001), and vaccinated cases had a longer time since vaccination compared to 
vaccinated controls (3.1 vs. 2.6 years, P = 0.01) (Table 1).
3.2. Varicella vaccine effectiveness
Overall varicella VE was 83.4% (95% confidence interval: 71.4–90.3), with age at 
vaccination (<15 months vs. ≥15 months) having little effect on varicella VE (88% vs. 
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82.4%, P = 0.59). Varicella VE did not vary significantly during the first five years after 
vaccination, ranging from 81.7% to 94.3% with average of 88.7%, but was significantly 
lower among those vaccinated more than five years before the outbreak (46.9%, P < 0.001) 
(Table 2, Fig. 1).
One dose VEs of Baike and Changsheng vaccines were 91.4% and 77.1% (P < 0.001 for 
both) respectively, with the difference between them statistically significant (P = 0.008). 
This difference in VE between the two vaccines remained significant even after addressing 
the differences in time since vaccination (25.2% among Changsheng recipients had been 
vaccinated ≥5 years prior to the outbreak vs. 0% among Baike recipients, P < 0.001). The 
VE for the Baike vaccine was greater than that of the Changsheng vaccine among those who 
had received vaccine within five years (91.4% vs. 84.5% for Baike and Changsheng, 
respectively, P = 0.02).
3.3. Varicella vaccination coverage
The overall vaccination coverage among the 19,488 students from the involved daycares (n 
= 21) and elementary schools (n = 23) was 41%, ranging from 0 to 93.8%. The vaccination 
status of the majority of vaccinated students (78.5%, 6261/7980) was verified with an 
immunization record from home with the rest based on parental recall. Elementary school 
students (n = 12,430) were more likely to be vaccinated than daycare attendees (n = 7058) 
(43.6% vs. 36.4%, P < 0.001) as were children of urban residency (n = 7018) compared to 
those from rural areas (n = 12,470) (44.2% vs. 39.1%, P < 0.001). These differences were 
largely driven by higher varicella vaccination coverage in urban compared to rural 
elementary schools (56.9% vs. 39.2%, P < 0.001) (Table 3).
4. Discussion
Our study showed that single-dose varicella vaccination in China was highly effective in 
preventing varicella in school settings. With varicella vaccine currently only available in 
China in the private sector, we found moderate varicella vaccination coverage had been 
achieved, although there was substantial variation across schools. Our study is the first to 
examine the effectiveness of two varicella vaccines (Baike and Changsheng) that are 
produced in China., which appear to offer comparable protection to Varilrix® and two other 
varicella vaccines from China (Shanghai and Changchun, now called Keygen) [13,17–19]. 
Though our study showed higher vaccine effectiveness for one of the vaccines, additional 
studies are needed to confirm or refute this finding. In our study, single-dose varicella 
vaccine-induced immunity appears to decrease 5 years after vaccination. This is similar to 
findings from an ecological study from the U.S. which reported that vaccine recipients were 
more than twice as likely to develop moderate/severe breakthrough varicella ≥5 years after 
vaccination compared to those who had been vaccinated more recently [20]. A retrospective 
cohort study in Turkey where varicella vaccine was also available only in private section 
found receipt of vaccination ≥5 years was associated with a more than three-fold likelihood 
of breakthrough varicella compared to more recent vaccination [21]. In contrast, a study of 
varicella VE changes after vaccination in Guangzhou China [13] did not find any 
statistically significant differences in VE during the seven years after vaccination. More data 
are needed to better understand the duration of protection in children after one dose varicella 
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vaccination, although this is increasingly challenging to investigate as disease circulation 
declines rapidly in many settings after introduction of varicella vaccination.
Because the effectiveness of single-dose varicella vaccination is approximately 85% against 
all varicella regardless of manufacturer [13,17,19,22], about 15% of vaccinated single-dose 
recipients may be incompletely protected against varicella. Over time, this proportion of 
vaccinated single-dose varicella recipients, which would increase along with increases in 
single-dose vaccine coverage [23], may become the driving force for school outbreaks 
[22,24,25]. Since two-dose varicella vaccination induces higher immunity and protection 
against varicella [26–28], some counties have implemented a 2-dose vaccine program 
among children to further reduce varicella disease burden and outbreaks [29–31]. Similar to 
the Varivax® and Varilrix®, several varicella vaccines manufactured in China, have been 
shown previously to have higher effectiveness against moderate/severe varicella than against 
all varicella [17,19,22]. Though not examined in this study, because they have been shown 
to offer similar protection against varicella of any severity as Varivax® and Varilrix®, it is 
likely that the two vaccines from China examined here (Baike and Changsheng) will have 
similar effect against moderate/severe varicella and in preventing varicella hospitalizations 
and deaths.
Moderate levels of varicella vaccination coverage have been achieved in selected areas in 
China. Given that varicella vaccine in China is currently only available in the private sector 
and currently priced at more than 25 US dollars for domestic varicella vaccine and 50 US 
dollars for imported varicella vaccine, the coverage levels achieved thus far suggest that 
varicella vaccination is well accepted in China among those who can afford it [3–5]. 
Achieving universal childhood varicella vaccination coverage while varicella vaccine 
availability is limited to the private sectors appears unlikely. Including varicella vaccine in 
the national or local immunization program could be a durable choice to achieve and 
maintain high vaccine coverage [2]. A potential disadvantage of achieving and maintaining 
only moderate levels of vaccination coverage is a decreased risk of varicella exposure for 
unvaccinated individuals during childhood which, over the long term, might cause a shift in 
the epidemiology of varicella that would result in an increase in the numbers of cases among 
older individuals who are more likely to develop severe outcomes if varicella occurs. For 
this reason, the World Health Organization recommends high (85–90%) and sustained 
routine vaccination coverage levels as a prerequisite for the introduction of a varicella 
vaccination program [32]. If fully implemented, in addition to reducing varicella among 
children, a routine childhood varicella vaccination program has the potential to reduce VZV 
exposure in infants who are too young to be eligible for vaccination, and adults, as well as 
those for whom vaccination is contraindicated but who remain at high risk of severe disease.
Several limitations should be considered in interpreting our findings. We employed a 
clinical case definition that did not require lab confirmation. Though medical practitioners in 
the study site were likely experienced in diagnosing varicella, their expertise with 
recognizing the milder clinical presentations of breakthrough varicella is unknown, therefore 
under-reporting of varicella in vaccinated persons may have occurred. If under-
ascertainment of cases in vaccinated children occurred, our VE estimate would an 
overestimation. The vaccination status was assessed at the end of school outbreaks, therefore 
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the vaccine coverage might be overestimated in that some children counted as vaccinated 
may have gotten vaccinated during the outbreaks. Moreover, using parental recall on 
vaccination status could have led to over- or under-estimation of true vaccine coverage.
In summary, single-dose varicella vaccine is highly effective in preventing varicella disease 
in school settings in China. Optimally, higher varicella vaccination coverage in China 
should be achieved and maintained during childhood to maximize the benefit of the varicella 
vaccine program in decreasing severe varicella morbidity and mortality for all age groups 
and to prevent epidemiology shift to adolescents and adults who are prone to develop severe 
outcomes if varicella occurs.
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Varicella vaccine effectiveness changes by time since vaccination.
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Table 1
Characteristics of the cases and the controls by exposure status in 44 schools, Tai’an prefecture, China, 2010–
2011.
Cases, No. (%) (n = 180) Controls, No. (%) (n = 679) P value
Sex 0.15
 Male 97 (53.9) 328 (48.31)
 Female 83 (46.1) 351 (51.69)
Age in years: mean (SD) 7.4 (2.2) 7.3 (2.1) 0.66
Having any underlying disease 1.0
 Yes 1 (0. 6) 5 (0.74)
 No 179 (99.4) 674 (99.26)
Type of school 0.33
 Elementary school 118 (65.6) 471 (69.37)
 Daycare 62 (34.4) 208 (30.63)
Varicella vaccination status <0.001
 Vaccinated 18 (10.0) 232 (34.17)
 Unvaccinated 162 (90.0) 447 (65.83)
Varicella vaccine producta,b 0.30
 Baike 3 (16.7) 80 (34.637)
 Changsheng 12 (66.6) 123 (53.25)
 GlaxoSmithKline 0 (0.0) 1 (0.43)
 Keygen 1 (5.6) 15 (6.49)
 Shanghai 2 (11.1) 12 (5.19)
Age at vaccinationa 0.62
 <15 months 3 (16.7) 37 (92.50)
 ≥15 months 15 (83.3) 195 (92.86)
Year since varicella vaccination:
 Mean (SD)a 4.1 (2.3) 2.9 (2.0) 0.01
a
Single-dose varicella vaccine recipients only.
b
One control with missing information on varicella vaccine product received.
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Table 2
Varicella vaccine effectiveness in a matched case–control study in elementary schools and daycares, Tai’an 
prefecture, China, 2010–2011.
Cases, No. (%) (n = 180) Controls, No. (%) (n = 679) Vaccine effectiveness (95% confidence interval)a P value
Overall VE
 Vaccinated 18 (10.0) 232 (34.2) 83.4 (71.4–90.3) <0.001
 Unvaccinated 162 (90.0) 447 (65.8) Reference
VE by age at vaccination
 <15 months 3 (1.7) 37 (5.5) 88.0 (55.3–96.8) 0.002
 ≥15 months 15 (8.3) 195 (28.7) 82. (68.8–90.0) <0.001
 Unvaccinated 162 (90.0) 447 (65.8) Reference
VE by time since vaccination
 <5 years 10 (5.6) 194 (28.6) 88.7 (77.7–94.3) <0.001
 ≥5 years 8 (4.4) 38 (5.6) 47.0 (0–79.2) 0.18
 Unvaccinated 162 (90.0) 447 (65.8) Reference
a
Vaccine effectiveness (VE) is defined as (1 − odds ratio) × 100.
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Table 3
Varicella vaccination coverage in 44 elementary schools and daycares (number of students = 19,488), Tai’an 
prefecture, China, 2010–2011.
Residence Type of school
Vaccinated students, No. (%) (n = 
7980)
Unvaccinated students, No. (%) (n = 
11,508) P value
Urban
Elementary school (n = 3) 1781 (56.9) 1350 (43.1) <0.001
Daycare (n = 11) 1323 (34.0) 2564 (66.0)
Rural
Elementary school (n = 20) 3633 (39.1) 5666 (60.9) 0.90
Daycare (n = 10) 1243 (39.2) 1928 (60.8)
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